Alzheimer’s Imaging Agents Should Be Validated With Autopsies, Panel Says
Executive Summary
Autopsy is the gold standard for confirming a diagnosis of Alzheimer's disease and should be used as the standard of truth in studies of imaging agents hoping to gain approval for amyloid plaque detection, an FDA panel unanimously concluded
You may also be interested in...
Standards For Molecular Imaging Agents Can Vary, Panel Tells FDA
The evidence needed to show efficacy and utility of a molecular imaging agent depends on what is being scanned and what claim is being sought, FDA's Peripheral and Central Nervous System Drugs Advisory Committee advised the agency Aug. 11
Standards For Molecular Imaging Agents Can Vary, Panel Tells FDA
The evidence needed to show efficacy and utility of a molecular imaging agent depends on what is being scanned and what claim is being sought, FDA's Peripheral and Central Nervous System Drugs Advisory Committee advised the agency Aug. 11
Alzheimer’s Report To Congress: Faster FDA Approval, Orphan-Like Exclusivity
The development of biomarkers and other steps to speed FDA approval of drugs for Alzheimer's disease was recommended by the Alzheimer's Study Group as part of a 1strategic plan presented to the Senate Select Committee on Aging March 25